Form 4: Emergent BioSolutions EVP Coleen Glessner Reports Stock and Options Grant

Coleen Glessner, EVP at Emergent BioSolutions, reports the acquisition of restricted stock units and employee stock options.

Summary

• Coleen Glessner, an EVP at Emergent BioSolutions, filed a Form 4 detailing changes in beneficial ownership.
• On March 6, 2025, Glessner acquired 62,500 restricted stock units (RSUs) and 62,500 employee stock options.
• The RSUs vest in three annual installments beginning on the day prior to the anniversary of the grant date.
• Each RSU represents the right to receive one share of Emergent BioSolutions common stock.
• The employee stock options, with an exercise price of $5.8, also vest in three equal installments beginning on the day prior to the anniversary date of the grant, and expire on March 5, 2032.
• Following these transactions, Glessner directly owns 176,656 shares of common stock and 249,613 derivative securities.

Sentiment

Score: 6

Explanation: The document is a neutral report of stock and option grants. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard executive compensation practices.

Positives

• The grant of RSUs and stock options to an executive could be seen as an incentive to align their interests with those of the shareholders.
• The vesting schedule encourages continued service with the company.

Future Outlook

The vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the executive.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. This filing indicates compensation and alignment of interests.

Stakeholder Impact

• The grant of equity to executives can align their interests with those of shareholders.
• Employees may view executive compensation as a reflection of company performance and values.

Key Dates